Chordia Therapeutics (TSE:190A) Net Margin %: 0.00% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Net Margin %?

Chordia Therapeutics TSE:190A -2.53% 11 Net Margin % is 0.00% as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Chordia Therapeutics ranks worse than 106157.01% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Chordia Therapeutics's Net Income for the six months ended in Feb. 2026 was 円-633.70 Mil. Chordia Therapeutics's Revenue for the six months ended in Feb. 2026 was 円0.00 Mil. Therefore, Chordia Therapeutics's net margin for the quarter that ended in Feb. 2026 was 0.00%.

The historical rank and industry rank for Chordia Therapeutics's Net Margin % or its related term are showing as below:


TSE:190A's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.295
* Ranked among companies with meaningful Net Margin % only.

Chordia Therapeutics  (TSE:190A) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Chordia Therapeutics Net Margin % Related Terms

Chordia Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Net Margin % Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Net Margin %
-65.89 0.00 8.93 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Net Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TSE:190A vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Chordia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's Net Margin % falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Chordia Therapeutics's Net Margin for the fiscal year that ended in Aug. 2025 is calculated as

Net Margin=Net Income (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-1785.867/0
= %

Chordia Therapeutics's Net Margin for the quarter that ended in Feb. 2026 is calculated as

Net Margin=Net Income (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=-633.703/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Chordia Therapeutics (TSE:190A) has a Net Margin % of 0.00% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Chordia Therapeutics' Net Margin % too high?
Chordia Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Chordia Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #999999 out of 942 companies for Net Margin %. This places Chordia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Net Margin % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price